Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Want to see CRVS full AI Analyst Report?
Soquelitinib, Cpi-818
Atopic Dermatitis, Eczema, Eczema, Atopic, Atopic Dermatitis Eczema
Phase II
Recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Feb 23, 2026
―
Belinostat, Soquelitinib, Pralatrexate
Lymphoma, T-Cell, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-Cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With Tfh Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral
Phase III
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Aug 16, 2024
Cpi-818
T-Cell Lymphoma
Phase I
Active Not Recruiting
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
May 07, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Corvus Pharmaceuticals Inc (CRVS) have in its pipeline
CRVS is currently developing the following drugs: Soquelitinib, Cpi-818, Belinostat, Soquelitinib, Pralatrexate, Soquelitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.